Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Cancer Research
  Year: 2006 | Volume: 2 | Issue: 4 | Page No.: 383-389
DOI: 10.3923/ijcr.2006.383.389
Role of Serum Lactate Dehydrogenase as a Bio-Marker in Therapy Related Hematological Malignancies
Rama Mani , S. Sudha Murthy and Kaiser Jamil

Abstract:
Lactate dehydrogenase (LDH) is a general indicator of the existence and severity of acute or chronic tissue damage. The present study aims to determine the LDH levels in patients with hematological malignancies to evaluate its role in the diagnosis and prognosis especially in Indian population. We have analyzed the serum LDH levels of 265 patients and the diagnosis included, 50 Acute Lymphocytic Leukemia (ALL) patients, 40 Non-Hodgkin`s Lymphoma (NHL) patients, 35 Chronic Myeloid Leukemia (CML) patients, 30 Acute Myeloid Leukemia (AML) patients, 15 Hodgkin`s Lymphoma (HD) patients, 20 Chronic Lymphocytic Leukemia (CLL) patients, 25 Multiple Myeloma (MM) patients and the remaining 50 are normal serum samples, taken for control group. Among these 215 blood cancer patients, 160 patients (74.41%) had shown abnormal levels of serum LDH compared to control group samples. Out of the 50 control group, only 02 (04%) people had shown elevated serum LDH levels. When serum LDH levels of 50 diagnosed patients were observed against their survival rates, patients with higher LDH levels were exposed to early relapse of their disease. Hence we can conclude from our results that serum LDH can be used as an important biomarker in diagnosis and prognosis of hematological malignancies.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Rama Mani , S. Sudha Murthy and Kaiser Jamil , 2006. Role of Serum Lactate Dehydrogenase as a Bio-Marker in Therapy Related Hematological Malignancies. International Journal of Cancer Research, 2: 383-389.

DOI: 10.3923/ijcr.2006.383.389

URL: https://scialert.net/abstract/?doi=ijcr.2006.383.389

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 

       

       

Curve Bottom